BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:SYHX1901 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of SYHX1901\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06943950-1927@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270428
DTEND;VALUE=DATE:20270429
SUMMARY:SYHX1901: Phase 3 readout est. (NCT06943950)
DESCRIPTION:SYHX1901\, phase 3\, Psoriasis.\nStudy: A Phase III Study of SY
 HX1901 Tablets in the Treatment of Moderate to Severe Plaque Psoriasis\nEs
 timated primary completion: 28 April 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/syhx1901#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06943950
URL:https://assetmemo.bio/drug/syhx1901#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06562894-1927@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:SYHX1901: Phase 2 readout est. (NCT06562894)
DESCRIPTION:SYHX1901\, phase 2.\nStudy: Study to Evaluate Safety and Effica
 cy of SYHX1901 Tablets in Severe Alopecia Areata Patients\nEstimated prima
 ry completion: 31 May 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/syhx1901#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06562894
URL:https://assetmemo.bio/drug/syhx1901#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
